Join our ImmunoCommunity and share your story!
"I would not be alive today if it were not for this drug."
When Pam Griffith, 65, was diagnosed with stage 3 lung cancer in March 2013, her doctors told her that it was aggressive but treatable. With surgery, chemotherapy, and radiation, she would likely be fine. But that summer, Pam and her husband, Randy, knew that something was wrong. Pam had begun to develop strange lumps in her neck and on the back on her head. A CT scan performed on August 23, 2013, showed that the cancer had spread to both lungs and her adrenal glands. Pam had progressed from stage 3 to stage 4.
At that point, Pam’s oncologist, Scott J. Antonia, M.D., Ph.D., of Moffitt Hospital in Tampa, FL, recommended that she consider entering a clinical trial of a new immunotherapy drug called nivolumab, made by Bristol Myers-Squibb. Nivolumab belongs to a class of drugs called checkpoint inhibitors, which block the “braking system” on T cells. The particular checkpoint that nivolumab targets is called PD-1. By “taking the brakes off” of T cells, nivolumab enables a stronger immune system response against cancer.
A happily retired real estate agent, with two children and six grandchildren, Pam knew that she wanted to fight the cancer in any way she could. The Answer to Cancer (TheA2C) spoke with Pam about her enrollment in the clinical trial and her experience with nivolumab.
Others may benefit from hearing your experience and treatment journey.
Sharon B. was shocked when she was diagnosed with stage 4 melanoma at age 22. She joined a clinical trial of the...
Like many men, Joe Blumberg, 71, didn’t know his “numbers” until after he got sick. Doctors told...
After Joanne Taylor was diagnosed with breast cancer in 2007, she had an idea: create a resource on the web for...
Join the ImmunoCommunity to access an important resource for all things related to cancer immunotherapy. Connect with others who have shared experiences and learn about new treatment options.
To continue to find the answers to cancer, it takes funding for research. Donate to the Cancer Research Institute today to help us continue to search for answers.